BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28289076)

  • 1. Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes.
    Kerins MJ; Vashisht AA; Liang BX; Duckworth SJ; Praslicka BJ; Wohlschlegel JA; Ooi A
    Mol Cell Biol; 2017 Jun; 37(11):. PubMed ID: 28289076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
    Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
    Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
    Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
    J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
    Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
    PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite.
    Perez M; Bak DW; Bergholtz SE; Crooks DR; Arimilli BS; Yang Y; Weerapana E; Linehan WM; Meier JL
    J Biol Chem; 2020 Sep; 295(39):13410-13418. PubMed ID: 32820045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.
    Ooi A; Furge KA
    Chin J Cancer; 2012 Sep; 31(9):413-20. PubMed ID: 22776233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
    Isaacs JS; Jung YJ; Mole DR; Lee S; Torres-Cabala C; Chung YL; Merino M; Trepel J; Zbar B; Toro J; Ratcliffe PJ; Linehan WM; Neckers L
    Cancer Cell; 2005 Aug; 8(2):143-53. PubMed ID: 16098467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
    Bayley JP; Launonen V; Tomlinson IP
    BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
    Merino MJ; Torres-Cabala C; Pinto P; Linehan WM
    Am J Surg Pathol; 2007 Oct; 31(10):1578-85. PubMed ID: 17895761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
    Tong WH; Sourbier C; Kovtunovych G; Jeong SY; Vira M; Ghosh M; Romero VV; Sougrat R; Vaulont S; Viollet B; Kim YS; Lee S; Trepel J; Srinivasan R; Bratslavsky G; Yang Y; Linehan WM; Rouault TA
    Cancer Cell; 2011 Sep; 20(3):315-27. PubMed ID: 21907923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
    Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
    BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.
    Alam NA; Rowan AJ; Wortham NC; Pollard PJ; Mitchell M; Tyrer JP; Barclay E; Calonje E; Manek S; Adams SJ; Bowers PW; Burrows NP; Charles-Holmes R; Cook LJ; Daly BM; Ford GP; Fuller LC; Hadfield-Jones SE; Hardwick N; Highet AS; Keefe M; MacDonald-Hull SP; Potts ED; Crone M; Wilkinson S; Camacho-Martinez F; Jablonska S; Ratnavel R; MacDonald A; Mann RJ; Grice K; Guillet G; Lewis-Jones MS; McGrath H; Seukeran DC; Morrison PJ; Fleming S; Rahman S; Kelsell D; Leigh I; Olpin S; Tomlinson IP
    Hum Mol Genet; 2003 Jun; 12(11):1241-52. PubMed ID: 12761039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency.
    Ternette N; Yang M; Laroyia M; Kitagawa M; O'Flaherty L; Wolhulter K; Igarashi K; Saito K; Kato K; Fischer R; Berquand A; Kessler BM; Lappin T; Frizzell N; Soga T; Adam J; Pollard PJ
    Cell Rep; 2013 Mar; 3(3):689-700. PubMed ID: 23499446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Kiuru M; Launonen V
    Curr Mol Med; 2004 Dec; 4(8):869-75. PubMed ID: 15579034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.
    Muller M; Guillaud-Bataille M; Salleron J; Genestie C; Deveaux S; Slama A; de Paillerets BB; Richard S; Benusiglio PR; Ferlicot S
    Mod Pathol; 2018 Jun; 31(6):974-983. PubMed ID: 29410489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction.
    Kerins MJ; Milligan J; Wohlschlegel JA; Ooi A
    Cancer Sci; 2018 Sep; 109(9):2757-2766. PubMed ID: 29917289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
    Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
    Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.